RecruitingNCT01730131
Neurological
Progressive multifocal leukoencephalopathy
7
studies recruiting now
as of 7 Sept 2026
32
studies registered in total
as of 7 Sept 2026
2
countries with a recruiting site
as of 7 Sept 2026
29 Jul 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNCT07732907
Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to Zeposia
RecruitingPhase 2NCT07511049
Intravenous Brincidofovir as an Antiviral for Treatment of Progressive Multifocal Leukoencephalopathy: A Pilot Study
RecruitingPhase 1NCT05849467
Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy
RecruitingNCT07512518
Observational Cohort Study of Chronic Viral Infection in the Central Nervous System
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 7 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Progressive multifocal leukoencephalopathy study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Progressive multifocal leukoencephalopathy
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.
Treatments being studied
3 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Phase 2/3Pembrolizumab (Keytruda)
Phase 1/2Mefloquine
Phase 1Efineptakin Alfa
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).